$138.10
-0.87[-0.63%]
At close: Apr 25
$138.10
0[0.00%]
After Hours: 4:56PM EDT
Neurocrine Biosciences
(NASDAQ:NBIX)Neurocrine Biosciences Stock (NASDAQ:NBIX), Analyst Ratings, Price Targets, Predictions
Neurocrine Biosciences Inc has a consensus price target of $132.29, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from Wells Fargo, Oppenheimer, and HC Wainwright & Co. on April 24, 2024. With an average price target of $173.33 between Wells Fargo, Oppenheimer, and HC Wainwright & Co., there's an implied 25.51% upside for Neurocrine Biosciences Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
Oppenheimer
HC Wainwright & Co.
Needham
Wedbush
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Neurocrine Biosciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/24/2024 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | 23.1% | Wells Fargo | Mohit Bansal | $140 → $170 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 04/24/2024 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | 44.82% | Oppenheimer | Jay Olson | $200 → $200 | Maintains | Outperform | Get Alert |
| 04/24/2024 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | 8.62% | HC Wainwright & Co. | Andrew Fein | → $150 | Reiterates | Buy → Buy | Get Alert |
| 04/23/2024 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | — | Needham | Ami Fadia | — | Reiterates | → Hold | Get Alert |
| 04/17/2024 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | 6.44% | Wedbush | Laura Chico | → $147 | Reiterates | Outperform → Outperform | Get Alert |
| 04/10/2024 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | 12.24% | Cantor Fitzgerald | Charles Duncan | → $155 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2024 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | 14.41% | JP Morgan | Anupam Rama | $148 → $158 | Maintains | Overweight | Get Alert |
| 03/13/2024 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | 44.82% | Oppenheimer | Jay Olson | $170 → $200 | Maintains | Outperform | Get Alert |
| 02/23/2024 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | 7.17% | JP Morgan | Anupam Rama | $154 → $148 | Maintains | Overweight | Get Alert |
| 02/08/2024 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | 1.38% | Citigroup | David Hoang | $141 → $140 | Maintains | Neutral | Get Alert |
| 02/08/2024 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | 1.38% | Mizuho | Uy Ear | $116 → $140 | Maintains | Neutral | Get Alert |
| 02/08/2024 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | 1.38% | Wells Fargo | Mohit Bansal | $127 → $140 | Maintains | Equal-Weight | Get Alert |
| 01/25/2024 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | 10.79% | Goldman Sachs | Chris Shibutani | $134 → $153 | Maintains | Buy | Get Alert |
| 01/23/2024 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | 8.62% | Barclays | Carter Gould | $145 → $150 | Maintains | Overweight | Get Alert |
| 12/18/2023 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | 4.27% | Stifel | Paul Matteis | $141 → $144 | Maintains | Buy | Get Alert |
| 12/13/2023 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | -8.04% | Wells Fargo | Mohit Bansal | $110 → $127 | Maintains | Equal-Weight | Get Alert |
| 12/13/2023 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | -8.04% | Citigroup | David Hoang | → $127 | Initiates | → Neutral | Get Alert |
| 12/12/2023 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | -1.52% | Deutsche Bank | Neena Bitritto-Garg | → $136 | Initiates | → Buy | Get Alert |
| 12/07/2023 | NBIX | Buy Now | Neurocrine Biosciences | $138.10 | 8.62% | Canaccord Genuity | Sumant Kulkarni | → $150 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Neurocrine Biosciences (NBIX)?
The latest price target for Neurocrine Biosciences (NASDAQ: NBIX) was reported by Wells Fargo on April 24, 2024. The analyst firm set a price target for $170.00 expecting NBIX to rise to within 12 months (a possible 23.10% upside). 61 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Neurocrine Biosciences (NBIX)?
The latest analyst rating for Neurocrine Biosciences (NASDAQ: NBIX) was provided by Wells Fargo, and Neurocrine Biosciences upgraded their overweight rating.
When was the last upgrade for Neurocrine Biosciences (NBIX)?
The last upgrade for Neurocrine Biosciences Inc happened on April 24, 2024 when Wells Fargo raised their price target to $170. Wells Fargo previously had an equal-weight for Neurocrine Biosciences Inc.
When was the last downgrade for Neurocrine Biosciences (NBIX)?
The last downgrade for Neurocrine Biosciences Inc happened on November 14, 2022 when Evercore ISI Group changed their price target from $140 to $130 for Neurocrine Biosciences Inc.
When is the next analyst rating going to be posted or updated for Neurocrine Biosciences (NBIX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neurocrine Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neurocrine Biosciences was filed on April 24, 2024 so you should expect the next rating to be made available sometime around April 24, 2025.
Is the Analyst Rating Neurocrine Biosciences (NBIX) correct?
While ratings are subjective and will change, the latest Neurocrine Biosciences (NBIX) rating was a upgraded with a price target of $140.00 to $170.00. The current price Neurocrine Biosciences (NBIX) is trading at is $138.10, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.